ResApp Health Limited advised it has signed a non-exclusive, two-year software licensing agreement with Workplace Medicine Australia Ltd. ("WMA"), to integrate ResApp's acute respiratory diagnostic test ResAppDx, in WMA's upcoming fully integrated and holistic workplace health and wellbeing management application, Medetective. WMA focuses on implementing state-of-the-art, evidence-based healthcare solutions to raise the standard for workplace health and wellbeing management, to ensure a healthy workforce and strengthen productivity within organisations. The group provides holistic medical screening and consultation services for corporate clients across a range of different industries including financial services, insurance, mining and construction. WMA will integrate ResAppDx into its new Medetective app, for use as a remote respiratory diagnostic aid alongside a telehealth consultation, reducing the need for employees to book in and travel to see a clinician for diagnosis. ResAppDx will be made available under the Medetective gold and platinum pricing tiers, which include on-demand telehealth medical consultations. ResAppDx uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone's built-in microphone. It is CE Marked in Europe and TGA approved in Australia.